Overview

* Rhythm Q3 2025 product revenue rises 54% yr/yr, driven by IMCIVREE sales

* Net income for Q3 2025 misses analyst expectations, larger loss reported

* FDA accepts sNDA for setmelanotide in acquired hypothalamic obesity, decision by Dec 20

Outlook

* Company expects FDA decision on sNDA by December 20, 2025

* Rhythm anticipates Q4 2025 results from Phase 2 trial in Prader-Willi syndrome

* Company updates 2025 Non-GAAP Operating Expenses guidance to $295 mln-$315 mln

Result Drivers

* U.S. SALES GROWTH - Revenue from U.S. sales increased 19% sequentially, driven by growth in IMCIVREE sales for BBS

* INTERNATIONAL SALES DECLINE - Revenue outside the U.S. decreased 21% sequentially due to ordering variability and a one-time pricing adjustment in France

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $51.29

Product mln

Revenue

Q3 Net Miss -$52.90 -$45.50

Income mln mln (11

Analysts

)

Q3 Basic -$0.82

EPS

Q3 -$52.65

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Rhythm Pharmaceuticals Inc ( RYTM ) is $121.50, about 6.4% above its November 3 closing price of $113.74

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)